Prognostic impact of HER-2 Subclonal Amplification in breast cancer

被引:15
|
作者
Di Oto, Enrico [1 ]
Brandes, Alba A. [2 ]
Cucchi, Maria C. [3 ]
Foschini, Maria P. [1 ]
机构
[1] Univ Bologna, Dept Biomed & Neuromotor Sci, Sect Anat Pathol, I-40139 Bologna, Italy
[2] AUSL Bologna IRCCS Inst Neurol Sci, Bellaria Hosp, Dept Med Oncol, I-40139 Bologna, Italy
[3] Bellaria Hosp, Breast Surg Unit, I-40139 Bologna, Italy
关键词
Breast cancer; HER-2; Subclones; Amplification; Prognosis; Therapy; INTRATUMORAL HETEROGENEITY; RECOMMENDATIONS; POLYSOMY;
D O I
10.1007/s00428-017-2151-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The presence of a limited number of cells with HER-2 amplification (Subclonal Amplification) in breast carcinomas is occasionally encountered, but its prognostic impact is poorly known. The purpose of this study is to evaluate the prognostic impact of HER-2 Subclonal Amplification in a retrospective series of breast cancers. Accordingly, 81 consecutive breast carcinomas showing HER-2 Subclonal Amplification were obtained from the histology files (case series). These cases were subdivided into two groups: (a) those cases in which the HER-2 Subclonal Amplification was consonant to the accepted criteria for amplification, showing clusters of amplified cells, and (b) those cases with rare HER-2 Subclonal Amplification that did not reflect the accepted criteria for amplification, showing scattered amplified cells only. The incidence of metastases and late recurrences of the case series was compared with a series composed of 109 consecutive cases, being HER-2 homogeneous (comprising 14 Amplified and 95 Non-Amplified cases), matched for grade and stage (control series). It appeared that cases showing Subclonal Amplification had an incidence of metastases intermediate between the cases Amplified and Non-Amplified. Specifically, Subclonal Amplification with clustered cells had a lower incidence of metastases than Amplified cases (12.9 versus 21.4%). On the contrary, Subclonal Amplification with scattered cells showed an incidence of metastases higher than Non-Amplified cases (14 versus 9.47%). In addition, patients Subclonal Amplification with clustered cells, who were treated with the specific monoclonal antibody, had a lower incidence of metastases than patients showing Subclonal Amplification with scattered cells, who did not receive target therapy. These data, together with those recently published, indicate that Subclonal Amplification has an impact on prognosis and should be taken into consideration to correctly plan the treatment of breast cancer patients.
引用
收藏
页码:313 / 319
页数:7
相关论文
共 50 条
  • [41] Recent trends of HER-2 testing and trastuzumab therapy for breast cancer
    Kurosumi, Masafumi
    BREAST CANCER, 2009, 16 (04) : 284 - 287
  • [42] What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?
    Giannone, Gaia
    Milani, Andrea
    Geuna, Elena
    Galizia, Danilo
    Biello, Federica
    Montemurro, Filippo
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (01) : 5 - 9
  • [43] The Role of Her-2/neu in the Carcinogenesis of Breast Cancer - When and Where?
    Rueschoff, J.
    Nagelmeier, I.
    Middel, P.
    Stoss, O.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (08) : 711 - 716
  • [44] Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer
    Varga, Zsuzsanna
    Tubbs, Raymond R.
    Wang, Zhen
    Sun, Yang
    Noske, Aurelia
    Kradolfer, Doris
    Bosshard, Giovanna
    Jochum, Wolfram
    Moch, Holger
    Oehlschlegel, Christian
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 925 - 935
  • [45] The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
    Ross, JS
    Fletcher, JA
    STEM CELLS, 1998, 16 (06) : 413 - 428
  • [46] Novel HER-2 Targeted Therapies in Breast Cancer
    Fernandes, Catarina Lopes
    Silva, Diogo J.
    Mesquita, Alexandra
    CANCERS, 2024, 16 (01)
  • [47] HER-2/neu and topoisomerase IIα in breast cancer
    Järvinen, TAH
    Liu, ET
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 78 (03) : 299 - 311
  • [48] INTERLABORATORY CONCORDANCE IN HER-2 POSITIVE BREAST CANCER
    Jonjic, Nives
    Mustac, Elvira
    Tomic, Snjezana
    Razumovic, Jasminka Jakic
    Sarcevic, Bozena
    Blazicevic, Valerija
    Labinac, Loredana Peteh
    Svagelj, Drazen
    Kopjar, Andrina
    Sikic, Natasa Lisica
    Vrbicic, Branka
    Boric, Igor
    ACTA CLINICA CROATICA, 2015, 54 (04) : 479 - 485
  • [49] Her-2/neu and Topoisomerase iiα in Breast Cancer
    Tero A.H. Järvinen
    Edison T. Liu
    Breast Cancer Research and Treatment, 2003, 78 : 299 - 311
  • [50] Correlation Between HER-2 Gene Amplification or Protein Expression and Clinical Pathological Features of Breast Cancer
    Shi, Pengfei
    Chen, Cheng
    Yao, Yufeng
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2019, 34 (01) : 42 - 46